Back to RecallTracker
Health Canada Health products

ZOLGENSMA (onasemnogene abeparvovec) and Fatal Cases of Acute Liver Failure

Issued September 12, 2022
Issue
Two cases of fatal acute liver failure associated with ZOLGENSMA have recently been reported internationally. The deaths occurred 6-7 weeks post-ZOLGENSMA infusion, following the initiation of corticosteroid taper. No fatal cases of acute liver failure have been reported in Canada.
Hazard description
New safety information
Product
Product name
ZOLGENSMA (onasemnogene abeparvovec)
Reference
ID
RA-64546